Clinical Materials. Orion shall be responsible for providing on a timely basis and against reimbursement of its Clinical Supply Costs all necessary quantities of Product and placebo for use in pre-clinical and clinical trials (including without limitation phase IV (“Phase IV”) and other post-marketing clinical studies) to be conducted by either Party pursuant to this Section 4.
Clinical Materials. As used herein, “Clinical Materials” shall means Licensed Product that has been manufactured, labeled and packaged in compliance with applicable laws relating to experimental materials to be administered to human test subjects.
Clinical Materials. MacroGenics shall be responsible for the cost of the supply of all Clinical Materials for the initial Phase I Clinical Trial;
Clinical Materials. Neurocrine shall use reasonable efforts to manufacture or have manufactured and supply to Ciba, and Ciba shall purchase from Neurocrine, such quantities of Collaboration Products as are reasonably required by Ciba to perform its obligations under the Development Program through Phase II trials in the United States pursuant to the Development * Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. Plan and Budget then in effect. All other Collaboration Products for use in the Development Program shall be manufactured or supplied by Ciba. The transfer price that Ciba shall pay to Neurocrine for quantities of such Collaboration Products pursuant to Section 6.2.2 shall be one hundred percent (100%) of Neurocrine's Manufacturing Costs of such Collaboration Products.
Clinical Materials. To the extent not already delivered on or prior to the Effective Date, MedImmune will deliver to Micromet the materials set forth in Exhibit D (the “Clinical Materials”) to be paid for by Micromet at the price set forth in Exhibit D (the “Price”). Except as set forth in this Section 4.1, MedImmune will not be obligated to supply Micromet with any Licensed Product, Clinical Materials or any products or materials used in or for the production of Licensed Product except for MedImmune’s obligations with respect to Media Materials under Section 5.2(b).
Clinical Materials. GWI may also submit POs for Clinical ------------------ Materials in bulk active or finished dosage form from time to time. Supplier agrees that it will manufacture and deliver Clinical Materials in accordance with the POs. [*] = CERTAIN INFORMATION ON THIS PAGE HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.
Clinical Materials. The Conversion Charge for Clinical Materials ------------------ shall be determined in the same manner as provided in Section 5.1(c) above for different pack or dosage sizes, as applicable; provided, appropriate reduction shall be made in the Conversion Charge so [*] = CERTAIN INFORMATION ON THIS PAGE HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. calculated for steps in production or packaging not required to be taken in connection with the production of such Clinical Materials.
Clinical Materials. To the extent that Biotest requests that ImmunoGen manufacture Clinical Materials, (A) the Parties shall share information concerning specifications, forecasting and capacity requirements in order to adequately plan for the manufacture and supply of such Clinical Materials and (B) ImmunoGen and Biotest shall enter into a separate supply and quality agreement detailing the terms of supply for any Clinical Materials that ImmunoGen is so requested to supply to Biotest, which supply agreement shall include, without limitation, the terms set forth on Schedule 3 attached hereto and the remainder of this Section 4.5.2(b)(iii) (the “Supply Agreement”). Subject to the foregoing, Biotest shall order all amounts of Clinical Materials, and ImmunoGen shall deliver all such ordered amounts in accordance with forecasting parameters, advance ordering timeframes and delivery timeframes to be agreed upon by the Parties in the Supply Agreement. The Supply Agreement further shall provide that (A) ImmunoGen shall use commercially reasonable efforts to deliver such amounts of Clinical Materials ordered in accordance with the foregoing (including such agreed upon timeframes) in a timely manner; provided, that, ImmunoGen’s obligations shall be contingent on ImmunoGen’s receipt of the required quantities of Anti-[***] Antibodies from Biotest and any Dedicated Equipment necessary to manufacture such Clinical Materials and (B) ImmunoGen’s transfer price to supply Clinical Materials to Biotest shall equal ImmunoGen’s Manufacturing Cost plus [***] ([***]%) percent for such Clinical Materials. Biotest hereby agrees that (i) it shall use the Clinical Materials in compliance with all Applicable Laws, and (ii) it (as a matter of contract between itself and ImmunoGen) shall assume all liability for damages that may arise from the use, storage and disposal of such Clinical Materials, except to the extent such liability for damages arises out of a failure on the part of ImmunoGen or any of its Affiliates to use the reasonably required diligence in the use, storage, and disposal of the relevant Clinical Materials. Biotest shall be entitled to transfer Clinical Materials to any Third Party under terms obligating such Third Party not to transfer or use such Clinical Materials except in compliance with the foregoing clause (i) of this Section 4.5.2(b).
Clinical Materials. Biorex shall use its best efforts to supply, ------------------ or to arrange for others to supply, Salix's requirements of Products for preclinical tests and human clinical trials on reasonable terms and conditions. In the event that Biorex arranges for Third Parties to develop formulations of, or supply, Products to Biorex under this Section 6.1, Biorex shall use all reasonable efforts to acquire the right to include the manufacturing processes and technology used by such Third Party for such Product in the Technical Information, Manufacturing Technology or the Patent Rights, so that Salix. may use such process to manufacture such Product.
Clinical Materials. Clinical materials (, for example, resource books, guides, tapes, videos) required by or related to workshops, courses, and other educational programs (, including on-line and independent study programs that provide nursing CEUs), will be covered under this benefit as approved by the unit manager. (The sitting fee for the initial certification paid for by the Employer does not count towards the nurse’s educational limit.)
